Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
05 now. This looks officially like a full blown scam now. Somebody is selling what he can every single day and on matter at what price.
Looking pretty good this one.
Yes, I am watching. Thanks for sharing.
MPME nice volume in today. 0.35 break will send it to test 0.6
Me too. Will take some profits then but will hold the rest.
MPME holding for dollar
Ah gotcha thanks. Forgot about that.
15M shares were cancelled. but TA hasn't updated there
Why does OTCM have the float larger than the OS?\
Outstanding Shares 64,418,954 a/o Aug 15, 2017
-Restricted 77,483,816 a/o Jul 31, 2017
-Unrestricted 1,935,138 a/o Jul 31, 2017
Held at DTC 1,775,138 a/o Jul 31, 2017
Float 1,557,000 a/o Apr 12, 2016
I tried this website and was told it doesn't exist. If you've already discussed this I'm sorry for wasting your time.
Interesting. Also has an increase in A/S today to 200 million.
MPME 10Q out. 64M OS, partnered with Mayo Clinic
Medisun Holdings Limited has partnered with the Mayo Clinic in Rochester, Minnesota to jointly establish an affiliated hospital network system in Hong Kong and Mainland China.
Mayo Clinic ranked #1 in the United States
Medisun’s NK cell technology provides us with treatment option for cancer. The NK cell technology is currently clinically used to treat cancer patients at Medisun’s network clinical facilities. We may seek to commercialize the NK cell technology and/or pursue strategic collaboration partnerships with other companies or clinical facilities.
What do you guys think of this? 3 August 2017 FORMAL DECLARATION BY MEDISUN GROUP
http://www.medisun.hk/image/data/Media/130_20170804/130_eng.pdf
With the termination agreement between the company and Zhengda and this formal declaration kind of makes you wonder whats going on.
FORM 8-K Filed 08/11/17
The Patent Assignment Agreement dated July 7, 2017
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12187849
Thanks funnyG. Your DD is great. Looks like we need to get the word out as one trade a day isn't going to cut it
Posting on the open topic boards like you have been doing should help.
I'll study up and see if I can find some funds to invest here.
Hi there and nice to see you here. Still working on my complete DD but other have provided some good DD.
I don't think they updated the web yet. Still linked to the old company. OS will be updated soon to show 15M less
Will check that out. In the meantime MPME email address not working and i do not see a website.
According to OTC it is a verified company profile.
Share Structure
Market Value1 $17,472,170 a/o Aug 11, 2017
Authorized Shares 100,000,000 a/o Jul 31, 2017
Outstanding Shares 79,418,954 a/o Jul 31, 2017
-Restricted 77,483,816 a/o Jul 31, 2017
-Unrestricted 1,935,138 a/o Jul 31, 2017
Held at DTC 1,775,138 a/o Jul 31, 2017
Float 1,557,000 a/o Apr 12, 2016
Par Value 0.0001
Transfer Agent(s) Verified by Transfer Agent
Nevada Agency and Transfer Company
Shareholders
Shareholders of Record 47 a/o Jun 22, 2017
Short Selling Data
Short Interest 10,780 (43.16%)
Jun 30, 2017
Significant Failures to Deliver No
I did DD Zhengda. they tried to RM into a shell in Hongkong exchange last year. but that didn't work out. not sure what they are planning. pretty big company though
Thanks funnyG986 for your post... I have been accumulating for a while now.
Are you able to elaborate more on this from 8k?
"On August 9, 2017, Medisun Precision Medicine Ltd. (the “Company”) entered into a settlement agreement (“Settlement”) with Zhengda Gene Life Science Shares Limited (“Zhengda”), a company incorporated in the Hong Kong Special Administrative Region of the People’s Republic of China (“PRC”), under which the Patent Assignment Agreement, dated July 7, 2017, between the Company and Zhengda was terminated. Pursuant to the Settlement, the Company assigned and transferred the Patent Rights back to Zhengda, while Zhengda returned the 15,000,000 Consideration Shares back to the Company. The foregoing descriptions are qualified in their entirety by reference to the Form of the Settlement which is filed herewith as Exhibit 10.1 to this Form 8-K and incorporated herein by reference."
I have tried reaching out to company but so far no results.
Thanks
MPME it clearly shows huge expansion ambition into China using the world class Cancer cure IP from Medisun with Local rich Bruno Wu.
1. Tiny float only 1.5M and more than 95% OS is held by insiders.
2. Medisun is one of the best hospital/Medical groups in the world.
3. Bruno Wu is a billionaire in China with personal wikipage showing his wealth
4. Medisun and Wu just launched a joint international clinic in China May 2017, right before all the name change 8k filings
5. All facts indicate they didn't buy MPME shell for no reason. MPME will be the trading symbol for their joint venture in mainland China.
Complete DD link
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133800390
Looks interesting. Need to look under the hood.
Do you have the DD bullet points?
MPME complete DD package here 08/13/2017
Tiny floater and only 1.7M shares at DTC
Authorized Shares 200,000,000 from recent pre14c
Outstanding Shares 64,418,954 from 8k 08/11/2017
-Restricted 62,483,816
-Unrestricted 1,935,138 a/o Jul 31, 2017
Held at DTC 1,775,138 a/o Jul 31, 2017
Float 1,557,000 a/o Apr 12, 2016
Chinese Billionaire Bruno Wu just took 15M shares here; went on noticed by market.
link to 8k July 24, 2017, MPME acquired some unknown company Sun Medical using 15M shares. Nothing substantial at the first glance.
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12187849
Item 1.01 Entry into a Material Definitive Agreement.
On July 24, 2017 (“Effective Date”), Medisun Precision Medicine Ltd. (the “Company”) entered into a share purchase agreement (“SPA”) with Sun Medical Operation Company Limited (“Sun Medical”), under which the Company acquired the entire issued share capital of New Sonic Global Limited (“New Sonic”) from Sun Medical. As consideration for the acquisition of New Sonic, the Company has agreed to issue to Sun Medical 15,000,000 new shares of the Company’s Common Stock.
Sun Medical is the sole registered and beneficial owner of all of the shares of New Sonic. Previously, Sun Medical entered into a cooperation agreement (“Cooperation Agreement”) with LDG Labor Deutschland (“LDG”) dated December 6, 2016, which has a supplemental agreement entered into between the Sun Medical and LDG dated April 12, 2017 (together with the Cooperation Agreement, collectively, the “Master Agreement”). Immediately before the signing of the SPA with the Company, the rights and obligations of Sun Medical under the Master Agreement was transferred to New Sonic in accordance with the Master Agreement by a transfer notice (“Transfer Notice”) given by Sun Medical to LDG. New Sonic was incorporated in the British Virgin Islands on May 15, 2017 and has had no operations except for the Master Agreement as its only asset.
If you go to page 9, you will find Bruno Zheng Wu signed on behave of SUN MEDICAL OPERATION COMPANY LIMITED
Who's this guy Bruno Zheng Wu? His Chinese name is Zheng Wu and English name is Bruno Wu. link to wiki page. This guy's net asset was US$510 million (October 2011) $$$$$$$$$$$$$$$$
https://en.wikipedia.org/wiki/Bruno_Wu
Bruno Wu, Ph.D.
Born 1966
Nationality Chinese
Alma mater Fudan University
Occupation Businessman
Known for Founder/Co-chairman and CEO of Sun Seven Stars Entertainment & Media Group Limited
Net worth US$510 million (October 2011)
Spouse(s) Lan YANG
How did I narrow down this one? see the wiki page showing Wu is the founder of Sun Seven Stars ? Search the previous 8k link, on page 7 the contact for Sun Medical showing email address with @sunsevenstars.com
(i)
in the case of the Vendor:
Address: Building A4 Fenghuayuan Drive-in Theater, No. 21 Liang Maqiao Road, Chaoyang District, Beijing, China, 100124
Fascimile number:
To be advised
Email address: avis.zhu@sunsevenstars.com
Attention: ZHU Yun
Some more DD added 08/12/2017
Medisun and Sun Medical started a clinic called Medisun-Sun Meicial International Clinic on 05/25/2017 in China. PR is in Chinese. link is here. http://www.sohu.com/a/143735059_508677
In the PR, they talked about big data in Medical applications and expansion in China.
You can zoom in to see the 2nd picture in the PR. it clearly shows both "Medisun" and "Sun Medical Group". The Guy on the right is Bruno Wu, the rich Chinese billionaire
Thanks. Will check it out.
LINK to MPME DD; Chinese billionare involved
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133796491
FORM 8-K Filed 08/11/17 The Patent Assignment Agreement dated July 7, 2017, between the Company and Zhengda was terminated. I wonder what happened.
Item 1.01 Entry into a Material Definitive Agreement.
On August 9, 2017, Medisun Precision Medicine Ltd. (the “Company”) entered into a settlement agreement (“Settlement”) with Zhengda Gene Life Science Shares Limited (“Zhengda”), a company incorporated in the Hong Kong Special Administrative Region of the People’s Republic of China (“PRC”), under which the Patent Assignment Agreement, dated July 7, 2017, between the Company and Zhengda was terminated. Pursuant to the Settlement, the Company assigned and transferred the Patent Rights back to Zhengda, while Zhengda returned the 15,000,000 Consideration Shares back to the Company. The foregoing descriptions are qualified in their entirety by reference to the Form of the Settlement which is filed herewith as Exhibit 10.1 to this Form 8-K and incorporated herein by reference.
The Company entered into the Patent Assignment Agreement with Zhengda on July 7, 2017, pursuant to which Zhengda assigned and transferred to the Company certain patent rights (“Patent Rights”) applied for registration in the State Intellectual Property Office of the PRC (patent application number: 201610218242) in relation to the isolation and culture method for primary mice or rat skeletal muscle cells. The Form of the Patent Assignment Agreement was filed as Exhibit 10.1 to the Form 8-K on July 10, 2017.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
10.1 Form of Settlement Agreement between the Company and Zhengda, dated August 9, 2017, and filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ACCUREXA INC.
Dated: August 11, 2017
By: /s/ Sophia Yaqi Sun
Name: Sophia Yaqi Sun
Title: President & CEO
https://www.sec.gov/Archives/edgar/data/1562107/000146970917000171/mpm8k_081117apg.htm
Thank you. i am looking forward to reading what you found. i have read about him too but cannot make the connection between what he does for a living and his stake in a neurological/chemo co.
MPME DDed the new stake holder Bruno Wu. Found Something amazing. Will post it later
Looks like Zhengda Gene Life Science Shares Limited took a 23% stake in the company. No shares left for trading...one PR and booom!
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12182497
kt
Interesting to see them bidding.
ACXA: effective June 30,2017 Accurexa Inc., ACXA, will change to Medisun Precision Medicine Ltd., MPME:
http://otce.finra.org/DLSymbolNameChanges
Ready for news .
Thanks. Will do.
Look at the code on the Form 4
Not award. Read the 8k
The purpose of the transaction and First License Agreement was to give Issuer the non-exclusive right to use the NK cell technology subject to certain conditions for 10 years in the United States and Greater China in exchange for the Reporting Person receiving 10,000,000 shares or 51.6% of the Issuer’s issued and outstanding common stock as of April 18, 2017. Concurrent to the License Agreement, Bryan Lee, Stefan Moll, and Oliver Jackson resigned their positions as directors and officers of
Issuer, and Issuer’s Board of Directors appointed Ms. Sophia Yaqi Sun as President, Chief Executive Officer, Chief Financial Officer, and Director. The Board of Directors also appointed Ms. Lisha Huang as Director. Pursuant to the License Agreement, the Issuer obtained the requisite approval to increase its authorized number of Common Stock to 100,000,000 shares. Issuer plans to acquire a controlling interest in a subsidiary of Medisun Holdings Limited. The purpose of the Second License Agreement was to expand the licensed regions to the rest of the world (i.e. other than the Greater China and the United States) in exchange for the Reporting Person receiving 30,000,000 shares of the Issuer’s common stock.
http://ih.advfn.com/p.php?pid=nmona&article=74982935
Some info on Ms. Yaqi Sun:
Prior to joining Medisun and NIF, Ms. Sun has worked for Ernest & Young LLP in Beijing and San Francisco, leading audit teams in financial auditing, bad debt evaluation, merger acquisition due diligence for commercial banks. Ms. Sun has obtained her Bachelor's degree at University of International Business and Economics in the People's Republic of China and her Master of Business Administration degree at the University of Illinois.
kt
That form 4 is not a purchase but an award.
That's tied in to the 8k that was out Friday.
http://ih.advfn.com/p.php?pid=nmona&article=74970789
On June 6, 2017, Accurexa Inc. (the “Company”) entered into a license agreement (“License Agreement”) pursuant to which Medisun Holdings Limited, a Hong Kong company (“Medisun”) granted the Company a non-exclusive license (“License”) to use Medisun’s NK (Natural Killer) cell technology in the rest of the world (i.e. other than the Greater China and the United States, which are the licensed regions in the First License Agreement between the Company and Medisun, dated on April 18, 2017 and filed on Form 8-K on May 17, 2017, as amended) from the date of License until the termination of the First License Agreement (“Term”). Medisun has developed its NK cell technology for the treatment of cancer. The NK cell technology is currently clinically used to treat cancer patients at Medisun’s network clinical facilities. The License provides that Medisun will provide to the Company any relevant technical advice and support from time to time as required by the Company during the Term.
As consideration for the License, the Company has agreed to issue to Medisun or its nominees 30,000,000 shares of the Company’s Common Stock. These shares were issued pursuant to Regulation D under the Securities Act of 1933, as amended (the “Act”), are exempt from registration under Section 4(2) of the Act, and bear an appropriate restrictive legend.
The foregoing descriptions are qualified in their entirety by reference to these documents, which are filed herewith as Exhibit 10.1 and incorporated herein by reference.
Item 3.02
Unregistered Sales of Equity Securities.
The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
On June 6, 2017, the Company agreed to issue to Medisun Holdings Limited, a Hong Kong corporation, (or its nominees, which is/are its subsidiary(ies)) and an accredited investor, 30,000,000 in shares of its Common Stock as consideration for entering into the License Agreement described in Item 1.01 of this Form 8-K.
The Company claims an exemption from the registration requirements of the Securities Act of 1933, as amended ("Act"), for the private placement of these securities pursuant to Section 4(2) of the Act since, among other things, the transaction did not involve a public offering, all parties are domiciled outside the United States, and Medisun (and its nominees) is an accredited investor, Medisun had access to information about the Company and its investment, accepted the securities for investment and not resale, and the Company took appropriate measures to restrict the transfer of the securities.
ACXA is not typical ihub play
ACXA FORM 4 showing shares acquired at $0.2
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1210
|
Created
|
06/27/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |